

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

2017 ANNUAL RESULTS OF CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.

This Announcement is made by PW Medtech Group Limited (the “**Company**”) pursuant to the requirements of Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Company’s announcement dated January 2, 2018 in respect of, among others, the closing of the Company’s subscription for shares of China Biologic Products Holdings, Inc. (“**CBPO**”) effective on January 1, 2018. As of the date of this announcement, the Company owns approximately 16.67% of the issued share capital of CBPO as the single largest shareholder.

CBPO, a major operating associate of the Company, is a company listed on The NASDAQ Stock Market LLC. On February 28, 2018, the board of directors of CBPO approved the release of its annual report for the year ended December 31, 2017 (the “**Annual Report**”). The Annual Report together with a press release announcing its audited financial results for the fourth quarter and the year ended December 31, 2017 (the “**Earnings Release**”) were filed with the United States Securities and Exchange Commission. A full text of the Annual Report and the Earnings Release can be visited at <https://www.sec.gov/cgi-bin/browse-edgar?CIK=cbpo&owner=exclude&action=getcompany&Find=Search>.

The audited consolidated financial statements of CBPO for the year ended December 31, 2017 (the “**CBPO Consolidated Financial Information**”) contained in the Annual Report have been prepared in accordance with the accounting principles generally accepted in the United States of America (the “**U.S. GAAP**”).

Set out below is a summary of the key items of the CBPO Consolidated Financial Information and non-U.S. GAAP adjusted financial information contained in the Earnings Release.

	For the year ended December 31, 2017 and as of December 31, 2017 (in United States dollars)
Sales	370,406,840
Gross profit	244,889,819
Net income attributable to CBPO	67,943,035
Total assets	809,057,417
Net assets	664,324,997
Non-U.S. GAAP adjusted net income attributable to CBPO	141,214,323

Shareholders and investors are reminded that the CBPO Consolidated Financial Information and its summary disclosed in this announcement are prepared in accordance with the U.S. GAAP, which are different from the Hong Kong Financial Reporting Standards used by the Company for preparing its consolidated financial statements, have not been reviewed or audited by the Company's independent auditor and may require adjustment during the course of review or audit. The non-U.S. GAAP adjusted net income is also not an alternative to CBPO's net profit as determined in accordance with the U.S. GAAP. In addition, the information contained in the Annual Report and the Earnings Release is limited solely to the consolidated operation of CBPO, which does not provide a full picture of the operation status of the Company and its subsidiaries.

Potential investors and shareholders of the Company are reminded not to place undue reliance on such information and should exercise caution when dealing with the securities of the Company.

By Order of the Board
PW Medtech Group Limited
Yue'e Zhang
Chairman

Beijing, the PRC, March 1, 2018

As at the date of this announcement, the Board comprises two executive Directors, namely, Ms. Yue'e Zhang and Mr. Jiang Liwei; one non-executive Director, namely Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Zhang Xingdong, Mr. Chen Geng and Mr. Wang Xiaogang.